44 completed, 15 unknown, 11 recruiting, 2 not yet recruiting. 25 Not applicable, 11 Phase 2, 7 Phase 4, 6 Phase 1, 3 Phase 3.
Follow Eye Manifestations: new trials by email Literature Review of Eye Manifestations trials Research Report on Eye Manifestations
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Acoltremon Ophthalmic Solution 0.003% on Tear Production and Symptoms in Patients With Tear Deficiency and Concurrent Neuropathic Corneal Pain acoltremon ophthalmic solution 0.003% - Ocular Pain, Dry Eye | Phase 4 | Not yet recruiting | University of South Florida | 28 | 2026-10-01 | 2026-10-06 |
| Study of EO2002 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction 150K cells, 500K cells, Placebo - Corneal Edema, Fuchs | Phase 2 | Recruiting | Emmecell | 121 | 2026-10-01 | 2026-10-09 |
| Phase 3, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Study Assessing the Safety and Efficacy of Urcosimod Ophthalmic Solution in Participants With Neuropathic Corneal Pain (NCP). Urcosimod ophthalmic solution is a preservative-free topical ophthalmic product; supplied in unit dose ampoules; administered QID for 12-weeks., Vehicle Ophthalmic Solution - Neuropathic Corneal Pain | Phase 3 | Not yet recruiting | Okyo Pharma Ltd | 111 | 2026-09-01 | 2026-09-29 |
| A Real-Time Magnetic Device Prototype for Temporary Management of Paralytic Lagophthalmos Magnetic device prototype - Paralytic Lagophthalmos | Not applicable | Suspended | E-DA Hospital | 12 | 2026-08-01 | 2025-08-14 |
| A Study of CA201A Eye Drops to Prevent Corneal Endothelial Cell Loss in Patients Undergoing Cataract Surgery Ophthalmic solution (matching formulation without ascorbic acid), Ascorbic acid ophthalmic solution 5% - Corneal Endothelial Cell Loss, Corneal Endothelial Damage Following the Hard Nuclear Cataract Surgery | Phase 2 | Recruiting | Caravel Oculus Pty Ltd | 200 | 2026-07-28 | 2026-08-06 |
| Effect of Systemic Ozone Therapy on Corneal Endothelium Systemic Ozone Therapy - Corneal Endothelial Cell Loss, Ozone Therapy | Not applicable | Completed | Yuzuncu Yil University | 96 | 2026-01-14 | 2026-07-21 |
| A Clinical Study to Determine What Effect the EyeCool Treatment Has on the Eye's Surface Anatomy and Inflammation Response After Being Treated for Having Chronic Ocular Surface Pain (COSP) Topical Ophthalmic Cooling - Eye Pain | Not applicable | Recruiting | EyeCool Therapeutics, Inc. | 5 | 2025-08-25 | 2026-05-26 |
| A Study to Assess Safety, Tolerability, and Pharmacokinetics of Ascending Concentrations of Topical Ocular BL1332 in Healthy Volunteers BL1332 ophthalmic solution, BL1332 ophthalmic vehicle - Ocular Pain | Phase 1 | Active not recruiting | Bausch & Lomb Incorporated | 24 | 2025-07-29 | 2026-01-27 |
| Phenotypic and Etiological Characterization of Susac Syndrome Susac Syndrome | Recruiting | Assistance Publique - Hôpitaux de Paris | 180 | 2025-07-01 | 2026-05-07 | |
| Suture Lid Spring for Lid Closure in Patients With Facial Nerve Palsy Polypropylene Suture Eyelid Spring for Paralytic Lagophthalmos - Facial Nerve Palsy, Corneal Exposure | Early Phase 1 | Recruiting | University of Alberta | 10 | 2025-04-28 | 2026-06-02 |
| Effect of Vitamin C Supplementation in Corneal Endothelial Damage in Phacoemulsification of Patients with Hard Cataracts Oral Vitamin C, Placebo - Endothelial Cell Loss, Corneal, Cataract and Intraocular Lens (IOL) Surgery | Not applicable | Recruiting | Universitas Indonesia | 120 | 2024-12-07 | 2025-01-17 |
| Validation of Ocular Pain Questionnaire: Single-center, Prospective Observational Study Ocular Pain, OSDI | Unknown | IRCCS Ospedale San Raffaele | 333 | 2024-11-01 | 2024-10-24 | |
| Efficacy and Safety of Topical Cyclosporine 0.05% and Lifitgrast on the Ocular Surface Symptom After Photorefractive Keratectomy in Feiz Hospital, Isfahan, 2024 Group 1 drug, Group 2: Drug and placebo, Group 3: Drug and palcebo - Ocular Surface Symptom, Ocular Surface Disease | Phase 1 | Unknown | Mohsen Pourazizi | 150 | 2024-10-30 | 2024-10-03 |
| Study of the ETX-4143 2.0 Device in Subjects With Eye Pain ETX-4143 2.0 - Eye Pain | Not applicable | Completed | EyeCool Therapeutics, Inc. | 31 | 2024-08-01 | 2025-08-22 |
| Self-Adhering Magnetic Device to Treat Corneal Exposure temporary magnetic system for tarsorrhaphy (MST) - Paralytic Lagophthalmos, Corneal Exposure | Not applicable | Recruiting | University of Illinois at Chicago | 25 | 2024-04-17 | 2026-05-22 |
| The Viability Control of Human Endothelial Cells Before Keratoplasty (V-CHECK) Study V-Check - Corneal Transplant Failure, Corneal Endothelial Cell Loss | Recruiting | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | 135 | 2023-12-01 | 2025-10-02 | |
| Corneal Endothelium in Diabetics Undergoing Phacoemulsification Corneal Endothelial Cell Loss | Unknown | Assiut University | 50 | 2023-11-01 | 2023-02-21 | |
| Efficacy of Quantum Molecular Resonance in Neuropathic Corneal Pain and Corneal Nerve Regeneration Quantum Molecular Resonance (QMR) Treatment - Neuropathic Corneal Pain | Not applicable | Recruiting | Singapore Eye Research Institute | 30 | 2023-11-01 | 2025-09-19 |
| Effect of Tiotropium on Eye Findings in the Treatment of Chronic Obstructive Pulmonary Disease Tiotropium - Chronic Obstructive Pulmonary Disease, Glaucoma, Angle-Closure | Completed | Giresun University | 108 | 2023-10-23 | 2024-07-29 | |
| Evaluate the TetraLens, a Tetracaine Releasing Therapeutic Bandage Contact Lens in Patients Undergoing PRK Procedure TetraLens bandage contact lens, Control Acuvue Oasys Bandage contact Lens - Ocular Pain | Early Phase 1 | Completed | Vance Thompson Vision | 10 | 2023-06-26 | 2025-09-17 |
Showing 20 of 78. Sign in to see all of them.
Eye Pain (29) · Corneal Endothelial Cell Loss (28) · Cataract (9) · Lagophthalmos (8) · Dry Eye Syndromes (7) · Corneal Edema (4) · Susac Syndrome (4) · Blepharoptosis (3) · Fuchs' Endothelial Dystrophy (3) · Glaucoma (3) · Macular Edema (3) · Bell Palsy (2) · Conjunctivitis (2) · Endophthalmitis (2)
Eye Diseases (77) · Pathological Conditions, Signs and Symptoms (71) · Signs and Symptoms (71) · Neurologic Manifestations (35) · Pathologic Processes (33) · Corneal Diseases (32) · Pain (29) · Postoperative Complications (28) · Nervous System Diseases (12) · Eyelid Diseases (10) · Lens Diseases (10) · Lacrimal Apparatus Diseases (8) · Retinal Diseases (8) · Arterial Occlusive Diseases (5)
Calcium Dobesilate (4) · Dexamethasone (3) · Ophthalmic Solutions (3) · Ascorbic Acid (2) · bromfenac (2) · prednisolone acetate (2) · Clemastine (1) · Diffusion Tensor Imaging (1) · Equipment and Supplies (1) · Lasers (1) · Lens Implantation, Intraocular (1) · Lubricant Eye Drops (1) · Methylprednisolone (1) · Oxymetazoline (1) · Phacoemulsification (1)
Cairo University (3) · Nicole Fram M.D. (3) · Sunnybrook Health Sciences Centre (3) · Sylentis, S.A. (3) · Assistance Publique - Hôpitaux de Paris (2) · Assiut University (2) · Biogen (2) · Charite University, Berlin, Germany (2) · EyeCool Therapeutics, Inc. (2) · Novartis Pharmaceuticals (2) · Topcon Medical Systems, Inc. (2) · University of California, San Francisco (2) · Akdeniz University (1) · Angeline Nguyen (1) · Asociación para Evitar la Ceguera en México (1)
United States (26) · Canada (6) · Germany (5) · Spain (5) · Turkey (Türkiye) (5) · Australia (3) · Egypt (3) · France (3) · Mexico (3) · United Kingdom (3) · Indonesia (2) · Iran (2) · Austria (1) · Belgium (1) · Bosnia and Herzegovina (1)
Nicole R Fram, M.D. (2) · Ahmed A Abdel Azim, MD (1) · Ahmed A. Dahab, MD (1) · Alireza Baradaran Raffiee, MD (1) · Angeline M Nguyen, MD (1) · Ari Green, MD, MCR (1) · Ayman GA Elnahry, Msc (1) · Belen Sadaba, MD, PhD (1) · Catherine Birt, MD (1) · Cynthia A Toth, MD (1) · David Hwang, MD (1) · Denise Ramjit (1)
PMID 27893109, PMID 36729473, PMID 26305528, PMID 28109276, PMID 30367938, PMID 31828475, PMID 33773011, PMID 34382290, PMID 36996503, PMID 37730252, PMID 38235955, PMID 39198799, PMID 39305913, PMID 39375488, PMID 39593673, PMID 39686647, PMID 39696716, PMID 41812852, PMID 42099442, PMID 42101550, PMID 42455250
2017 (1), R01EY023039 (1)